Preview

Safety and Risk of Pharmacotherapy

Advanced search

Changes to the EAEU Guideline on Good Pharmacovigilance Practices

https://doi.org/10.30895/2312-7821-2023-11-1-336

Abstract

By Decision No. 81 of 19.06.2022, the Council of the Eurasian Economic Commission amended the Guideline on Good Pharmacovigilance Practices of the Eurasian Economic Union (EAEU GVP Guideline), the core regulatory document on pharmacovigilance requirements for the EAEU Member States. The amendment involved all critical pharmacovigilance processes, and its consequences are yet to be assessed.
The aim of the study was to analyse the changes to the EAEU GVP Guideline effective since 06.12.2022.
The author summarised information on the changes made to the EAEU GVP Guideline by Decision No. 81 of the Council of the Eurasian Economic Commission of 19.06.2022 “On Amendments to the Rules of Good Pharmacovigilance Practice of the Eurasian Economic Union”. He described the differences between the old and the new versions of the EAEU GVP Guideline. Having critically reviewed the updated regulatory document, the author commented on its positive and negative aspects. The review created a starting point for further analysis of the changes to the EAEU GVP Guideline. At the time of writing, there were no other published works assessing the significance of most of the changes for the pharmaceutical industry and designated pharmacovigilance organi­sations in the EAEU Member States. The author assessed their significance through the prism of the recent years’ events in Russia and the world, including the COVID-19 pandemic. In connection with the amended guideline coming into force in 2022, the author suggested a transitional standstill period for both the pharmaceutical industry and designated pharmacovigilance organisations. He offered further improvements for the guideline. The article may be of practical interest to pharmacovigilance specialists, heads of pharmaceutical organisations, and employees of regulatory authorities.

About the Author

B. K. Romanov
N.I. Pirogov Russian National Research Medical University
Russian Federation

Boris K. Romanov, Dr. Sci. (Med.), Associate Professor

117997, Moscow, Ostrovityanova St., 1



References

1. Asetskaya IL, Zyryanov SK, Kolbin AS, Belousov DYu. Pharmacovigilance system in Eurasian Economic Union. Good Clinical Practice. 2018;(4):53–72 (In Russ.). https://doi.org/10.24411/2588-0519-2018-10059

2. Gorelov KV. Development problems of the pharmacovigilance system in the Russian Federation. Medical Ethics. 2020;(1):15–9 (In Russ.).

3. Koryanova KN, Matveev AV, Egorova EA, Bekirova EYu. Features of international and regional pharmacovi­gilance systems. Regionology. 2020;28(3):571–97 (In Russ.). https://doi.org/10.15507/2413-1407.112.028.202003.571-597


Supplementary files

Review

For citations:


Romanov B.K. Changes to the EAEU Guideline on Good Pharmacovigilance Practices. Safety and Risk of Pharmacotherapy. 2023;11(1):14-21. (In Russ.) https://doi.org/10.30895/2312-7821-2023-11-1-336

Views: 3472


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2312-7821 (Print)
ISSN 2619-1164 (Online)